Thermo Fisher Scientific
Understanding a molecule’s product quality attributes (PQAs), including their effect on structure–function relationships and long-term stability, is essential to ensure the safety and efficacy of biotherapeutics.
A multi-attribute method (MAM), based on LC-MS peptide mapping and automation principles, can offer a faster, more efficient method of characterizing and monitoring PQAs than the current plethora of routine chromatographic and electrophoretic assays.
Watch this free webinar to learn how MS-based MAM provides simultaneous detection, identification, quantitation and quality control (monitoring) of PQAs. The webinar covers how a dedicated team at Pfizer developed a multi-site “Lab-of-the-Future” for streamlined MAM analyses.
Duration: 1 hour
Andrew Dawdy, Principal Scientist, Pfizer
Andrew Dawdy is a principal scientist at Pfizer in their core mass spectrometry group within the “Biotherapeutics Pharmaceutical Sciences” division. He and his colleagues use a variety of mass spectrometry techniques to perform heightened characterization of a wide variety of biotherapeutic modalities, including mAbs, bispecifics, ADCs, vaccines, gene therapies, and more. For the last three years, he has worked as a member of Pfizer’s multi-attribute method (MAM) team to develop and launch Pfizer’s MAM platform.
* Required field